Compare Jabil Inc (JBL) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jabil Inc vs Novartis AG — how do they compare? Jabil Inc trades at $366.58 (market cap $37.37B), while Novartis AG trades at $153.04 (market cap $295.37B). The key difference: Novartis AG is far larger — about 7.9× Jabil Inc's market cap, and Novartis AG pays the higher dividend (3.07%). Which is the better fit depends on your goals.
| JBL | NVS | |
|---|---|---|
Market Cap | $37.37B | $295.37B |
Sector | Technology | Health |
52-Week High | $385.50 | $168.62 |
52-Week Low | $192.49 | $119.31 |
Enterprise Value | $39.90B | $336.69B |
Dividend Yield | 0.09% | 3.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Jabil (JBL) trades at $366.10, up 8.75% in 24 hours, reflecting strong momentum driven by AI infrastructure demand. The stock shows bullish technical signals with a consensus price target of $448.29, indicating 22% upside. Recent earnings beats and projected AI revenue growth to over $20 billion by fiscal 2027 (UBS, August 11, 2026) support optimism, though high P/E of 44.63 and thin net margins near 2.6% warrant caution.
Outlook is positive with AI-driven expansion, but risks include valuation sensitivity and competitive pressures. Investment appeal hinges on execution of growth forecasts, while volatility may arise from macroeconomic shifts or supply chain disruptions.
Novartis AG (NVS) trades at $156.79, up 0.29% today, with a bullish technical signal from moving averages and recent Q2 2026 earnings beating estimates. Strong profitability is evident with a 74.74% gross margin and 22.5% net margin, while revenue grew to $56.67B in 2025. The stock faces resistance near $157, with support at $156.
The outlook is positive due to robust drug pipeline progress and reaffirmed 2026 guidance, though risks include generic competition for Entresto and pricing pressures. Analyst sentiment is mixed with 24% buy ratings, but institutional buying activity supports confidence in long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
